reviews. After merging similar questions, 104 were distributed for voting. From the 30 most popular uncertainties, the top 15 questions were prioritised in a facilitated workshop. These include prevention and prediction of preterm birth, neonatal infection, lung damage, necrotising enterocolitis, pre-eclampsia, preterm premature rupture of the membranes, optimal neonatal feeding strategy, pain perception and management, a care package at neonatal discharge, emotional and practical support, attachment and bonding, and the best time for cord clamping.

Conclusions These priorities provide guidance to ensure that future research addresses questions that are important to service users and clinicians. Challenges for the priority setting partnership included maximising participation amongst people most affected by preterm birth, the breadth of the topic and securing input from an appropriate range of clinicians.

Feeding Regimen

**PS-053** VARIABILITY IN ADIPOKINES PROFILE OF NEWBORNS AND THEIR MOTHERS AFTER DHA SUPPLEMENTATION IN PREGNANCY

1 E Martin Alvarez, 2 M Peña-Caballero, 3 I Hartado-Suazo, 4 N Kajarabille, 5 F Lara-Villoslada, 6 JI Ochoa, 7 Paediatric, Hospital Universitario Virgen de Las Nieves, Granada, Spain; 8 Nutrition, Institute of Nutrition and Food Technology “José Mataix”, Granada, Spain; 9 R&D Department, Lactalis Pulèva, Granada, Spain

Background/aims Most studies of DHA supplementation during pregnancy and infant development are focused on visual and neural development. However, scarce information is available about the influence of DHA supplementation on adipokines expression, which are related to adipose tissue metabolism and obesity.

Aim To evaluate the effect of DHA supplemented dairy drink consumption during pregnancy and breastfeeding on the expression of several adipokines in mothers (pregnancy, delivery and breastfeeding) and their newborns (birth and 2.5 months of age).

Methods 60 women were randomly assigned to two intervention groups: A) Control Group (n = 30); B) Supplemented Group (n = 30): The women took 2 glasses/day of the supplemented drink (400 mg DHA/day). Dietary intervention began in week 28th of pregnancy and concluded when breastfeeding stopped. Samples of blood were obtained from: the mothers, the umbilical vein and artery; the newborn at 2.5 months postpartum. Adiponectin, resistin, leptin and active PAI-1 plasma levels were determined using a panel from Lumixen xMAP technology.

Results Adiponectin was higher in the supplemented group in umbilical cord artery, whereas active-PAI showed a lower value in this group, although we observed an increase in mother’s blood during delivery. Resistin did not show any difference. Leptin was higher in the supplemented group in umbilical cord.

Conclusion The most noteworthy result is the effect of DHA supplementation in umbilical cord artery adipokine levels, increasing the adiponectin and decreasing the active PAI-1. In addition, active PAI-1 increases in mothers during delivery. It is also interesting the increase in the supplemented group of leptin.

**PS-054** VSL#3 SUPPLEMENTATION TO MOTHERS DURING PREGNANCY AND BREAST FEEDING IMPROVES COLICS AND REGURGITATION IN NEWBORNS, PERHAPS BY TGF-B MODULATION

1 ME Bálldassarre, 2 P Mastromarino, 3 A Micheli, 4 M Fanelli, 5 A Dileone, 6 P Dilmaco, 7 N Laforgia. 1 Department of “Scienze Biomediche ed Oncologia Umana” - Neonatology and NICU Section, University of Bari, Bari, Italy; 2 Department of Public Health and Infectious Diseases, University “La Sapienza”, Rome, Italy; 3 Department of Chemistry, University “La Sapienza”, Rome, Italy; 4 Department of Internal Medicine and Public Health - Section of Nuclear Medicine-Medical Statistics, University of Bari, Bari, Italy

Aim To evaluate the influence of maternal supplementation with VSL#3 on digestive events in newborns and cytokines levels in colostrum and mature breast milk.

Methods This pilot double-blind, randomised, placebo-controlled clinical trial (clinicaltrials.gov: NCT01367470) enrolled four weeks before expected delivery healthy pregnant women that received daily oral VSL#3 (PTM) or placebo (CM) supplementation until four weeks after delivery. In milk samples we...